Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw

Takazumi Yasui; Moemi Kimura; Hiroki Nagamine; Shosuke Yajima; Takeshi Karube; Hitoshi Sato; Seiji Asoda; Satoshi Hara; Katsuhiro Onizawa

doi:10.1016/j.oooo.2020.12.018

Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw

Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Mar;131(3):312-318. doi: 10.1016/j.oooo.2020.12.018. Epub 2020 Dec 26.

Authors

Takazumi Yasui¹, Moemi Kimura², Hiroki Nagamine³, Shosuke Yajima⁴, Takeshi Karube⁵, Hitoshi Sato⁶, Seiji Asoda⁵, Satoshi Hara⁷, Katsuhiro Onizawa³

Affiliations

¹ Department of Dentistry and Oral Surgery, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan; Department of Dentistry and Oral Surgery, School of Medicine, Keio University, Tokyo, Japan. Electronic address: tyasui@kmh.gr.jp.
² Department of Dentistry and Oral Surgery, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan; Department of Dentistry and Oral Surgery, School of Medicine, Keio University, Tokyo, Japan.
³ Department of Dentistry and Oral Surgery, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan.
⁴ Department of Dentistry and Oral Surgery, Kawasaki Municipal Ida Hospital, Kawasaki, Japan.
⁵ Department of Dentistry and Oral Surgery, School of Medicine, Keio University, Tokyo, Japan.
⁶ Department of Oral and Maxillofacial Surgery, Division of Oral Oncology, Showa University, School of Dentistry, Tokyo, Japan.
⁷ Department of Urology, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan.

PMID: 33431343
DOI: 10.1016/j.oooo.2020.12.018

Abstract

Objective: The aim of this study was to evaluate the risk of osteonecrosis of the jaw (ONJ) in patients with prostate cancer, particularly the relationship between prostate cancer progression and ONJ development.

Study design: This single-center, retrospective, observational study included 113 patients who received zoledronic acid or denosumab for prostate cancer with bone metastasis between January 2012 and March 2020. The risk of ONJ was evaluated regarding age; antiresorptive drugs; duration of antiresorptive treatment; prostate cancer status, including castration-resistant prostate cancer (CRPC) and prostate-specific antigen level; chemotherapy; radium-223 treatment; corticosteroid treatment; diabetes mellitus; and dental extractions.

Results: Overall, 28 patients had ONJ; 10 patients received zoledronic acid and 18 patients received denosumab. Multiple logistic regression analysis demonstrated that CRPC (odds ratio = 6.01; 95% confidence interval, 1.76-20.05; P = .004) and dental extractions (odds ratio = 12.40; 95% confidence interval, 3.42-44.70; P < .001) were significantly associated with ONJ. In addition, antiresorptive treatment lasting more than 1 year partially mediated between CRPC and development of ONJ.

Conclusion: CRPC and dental extraction are risk factors for developing ONJ, and antiresorptive treatment lasting more than 1 year is a partial mediator between CRPC and ONJ.

Publication types

Observational Study

MeSH terms

Bisphosphonate-Associated Osteonecrosis of the Jaw* / epidemiology
Bone Density Conservation Agents* / adverse effects
Denosumab / adverse effects
Diphosphonates / adverse effects
Humans
Male
Osteonecrosis*
Prevalence
Prostatic Neoplasms* / drug therapy
Risk Factors

Substances

Bone Density Conservation Agents
Diphosphonates
Denosumab